ONCOLYTICS BIOTECH INC ONCY
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
1/9
Piotroski F — financial health
-209.84
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | — | -$28.8M | — | -$20.1M | -$3.8M |
| 2024 | — | -$22.8M | — | -$20.1M | $3.3M |
Why these scores methodology →
Piotroski F-score: 1/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -209.84 (distress)
- Working capital / assets 0.098
- Retained earnings / assets -56.647
- EBIT / assets -3.789
- Equity / liabilities -0.334
Source: SEC EDGAR filings · CIK 0001129928 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.